| Objective: To study the purpose of PEG interferonα-2 a treatment of chronic hepatitis B patients with the EVR to the SVR relationship. Methods: We collected from May 2005 to November during 2007, in China and Japan Union Hospital digestive department of Jilin University, diagnosis and choose to CHB PEG interferonα-2 a treatment of patients with a total of 40 patients, 22 men, 18 women , Of which 22 patients with HBeAg-positive, HBeAg negative 18 patients, aged 16 to 43-year-old. An average of 29±11.5 years old, the course was 1 to 20, the ALT / AST normal serum HBV DNA positive (a total of 12 cases, five cases of men and 7 women, age 25 to 53 years old, the average age of 37.4±8.47) Huotizuzhi of liver puncture. All patients were using PEG interferonα-2 a (40KD) 180μg weekly subcutaneous injection of one course of 48 weeks, treatment were followed up after the end of 24 weeks. Diagnosis in December 2005 Chinese Medical Association and the liver credits of Chinese Medical Association of Credit and the Chinese Hepatitis Prevention Foundation, a joint set of "Chronic Hepatitis B prevention and treatment guidelines" established standards. Application of ELISA (ELISA) HBsAg, HBsAb, HBeAg, HBeAb, HBcAb. Use LX-200 automatic biochemical analyzer detecting chemical health indicators. Using real-time fluorescence quantitative polymerase chain reaction (FQ-PCR) method of serum HBV DNA content; polymerase chain reaction - micro-nucleic acid hybridization - ELISA method detection HBV DNA genotypes. Results: Of the 40 cases of PEG interferonα-2 a treatment of chronic hepatitis B patients with follow-up study, treatment HBV DNA at 12 weeks contained 48 weeks of treatment and 24 weeks after stopping at the rate of HBV DNA unpredictable, ALT normalization Rate, HBeAg loss and serum HBeAg conversion rates showed that the relationship: HBeAg-positive chronic hepatitis B patients with 22 cases, the treatment of 12 weeks of serum HBV DNA load <3 log10copies/ml patients in the follow-up after stopping at 24 weeks HBV DNA unpredictable rate, ALT normalization rate and HBeAg negative serum HBeAg and the conversion rate was significantly higher than that for 12 weeks of serum HBV DNA load between 3 log10copies/ml-5log10copies/ml and HBV DNA contained in≥5 log10copies/ml The patients P <0.001; HBeAg negative of the 18 patients with chronic hepatitis B patients in the treatment of 12 weeks of serum HBV DNA load <3 log10copies/ml patients in the follow-up 24 weeks after stopping at the rate of HBV DNA unpredictable, ALT normalization rate For 12 weeks was significantly higher than that of serum HBV DNA load between 3 log10copies/ml-5log10copies/ml and HBV DNA contained in≥5 log10copies / ml in patients with P <0.001; PEG interferonα-2 a treatment in HBeAg Positive chronic hepatitis B patients for 12 weeks and 24 weeks, 36 weeks, 48 weeks and 12 weeks after treatment follow-up and 24 weeks, HBeAg loss of access to the continuous increase, respectively, 7% and 12%, 17%, 21 %, 27%, 36%; HBeAg-positive chronic hepatitis B patients in the treatment of 12 weeks has not found serum HBeAg conversion, and the treatment of 24 weeks, 36 weeks and 48 weeks and 12 weeks after treatment and follow-up 24 weeks of serum HBeAg Of conversion rates were 4%, 4%, 8%, 12%, 17%; PEG interferonα-2 a treatment of chronic hepatitis B patients and the rate of HBsAg disappeared HBsAg serum conversion rate: in the treatment of 36 weeks Not one case of the former patients HBsAg disappeared in 36 weeks and 48 weeks after treatment and follow-up of 12 weeks and 24 weeks in the course of their HBsAg loss rates were: 4%, 7%, 12%, 14%; HBsAg serology Conversion rate, in the treatment of 48 weeks before failing a case of the patients serum HBsAg conversion, 48 weeks after treatment and follow-up of 12 weeks and 24 weeks in HBsAg serology conversion rates were 2%, 2%, 4.8%; PEG interferonα-2 a chronic hepatitis B patients on the efficacy of different genotypes, the results showed that 40 cases of patients with chronic hepatitis B to C genotype-based, accounting for 60 percent, followed by 33 per cent B genotypes, and D, A genotype less, only accounted for 5% and 2%. One B genotypes in patients with chronic hepatitis B treatment of 12 weeks, 24 weeks, 36 weeks, 48 weeks and 12 weeks after treatment and follow-up in the course of 24 weeks ALT normalization rates were: 18%, 28%, 35% 42%, 49%, 53%; HBV DNA unpredictable rates were 14% and 20%, 25% and 32%, 36%, 41%, while genotype C ALT normalization rates were 13%, 20%, 27%, 33%, 40%, 46%; HBV DNA unpredictable rate of 9%, 15% and 19%, 25% and 29%, 33%, compared between the two groups P <0.05; polyethylene glycol Interferonα-2 a liver disease in patients with chronic hepatitis B on grounds of the impact of the Organization showed that the treatment of patients with chronic hepatitis B after liver fibrosis staging grounds and inflammatory activity had been significantly improved the situation of adverse reactions, 40 Patients with chronic hepatitis B patients with symptoms of fever occurred in 53 percent of all patients after treatment WBC, in varying degrees of platelet decline. Conclusions: PEG interferonα-2 a treatment of chronic hepatitis B patients lasting response and early response are closely related, 12 weeks of serum HBV DNA load <3 log10 copies / ml in patients 24 weeks after treatment HBV DNA unpredictable rate, ALT normalization rate and HBeAg loss and serum HBeAg conversion rates are significantly higher; PEG interferonα-2 a treatment in HBeAg-positive chronic hepatitis B patients, with the extension of the treatment, HBeAg loss and the conversion of serum HBeAg Rate, HBsAg disappeared and the rate of HBsAg serum conversion rate gradually increased, and after treatment is still a sustained rise in the region of patients with chronic hepatitis B to C genotype-based, followed by B genotype. PEG interferonα-2 a treatment of patients with genotype B, superior efficacy in patients with genotype C; PEG interferonα-2 a treatment of chronic hepatitis B patients, can significantly improve the rationale for fibrosis stage liver disease and inflammatory Activity.
|
PDF Full Text Request